ACTG A5229 (VS 10):TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究将试图了解服用尿苷补充剂NucleomaxX对HIV感染者是否安全，以及它是否会逆转面部、手臂、腿部或臀部的脂肪损失。该研究还将尝试观察研究药物的耐受性。 研究药物是一种粉状营养食品补充剂，含有一种称为尿苷的物质。它装在一个小袋里，需要和果汁、牛奶或水混合。该研究药物在欧洲用作食品补充剂，但未经美国食品药品监督管理局（FDA）批准，在美国被视为实验性药物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will try to see if taking a uridine supplement, NucleomaxX¿, is safe in HIV-infected persons and if it will reverse loss of fat in the face, arms, legs, or buttocks. The study will also try to see how well the study drug is tolerated. The study drug is a powdered nutritional food supplement that contains a substance called uridine. It comes in a sachet (packet) and needs to be mixed in with juice, milk, or water. The study drug is used in Europe as a food supplement but is not approved by the U.S. Food and Drug Administration (FDA) and is considered an experimental drug in the U.S.